Clinical Trial Update: Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons [Phase 1, Phase 2]

View source ↗

Summary

This trial update reports on the immunogenicity and safety of an adjuvanted Epstein-Barr virus glycoprotein 350 vaccine evaluated in EBV-seronegative adults in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection
• Infectious Mononucleosis

Drugs mentioned

• Adjuvanted Epstein-Barr virus glycoprotein 350 vaccine (Epstein-Barr virus glycoprotein 350 vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Epstein-Barr Virus Infection, Infectious Mononucleosis | Phase 1, Phase 2 | Status: COMPLETED